REPORT

3rd meeting of the ACTE ADVISORY BOARD FOR AN INDEPENDENT STUDY INTO
THE IATA CORPORATE CLIENT IDENTIFICATION SERVICE (CCIS)

- via conference call -
6 July 2001

Agenda Item 1: Opening of Meeting

1. The Chairperson of the Advisory Board, Nancy Holtzman (ACTE), opened the meeting via conference call at 0900 hours EST on Friday, 6 July 2001.  The attendance list is shown in Attachment A.  She welcomed two new corporates to the Advisory Board: Dan Baillie (Block Drug Company) and Clive Armitage (Astra Zeneca Pharmaceuticals).  This brings the total of corporates on the board to five.

Agenda Item 2: Approval of the Report of Last Meeting (12 June 2001)

2.  The report was approved.  However, it was re-iterated that more corporate participation was essential to the success of this study.  Furthermore, the development of a data flow chart was becoming urgent. The Secretary agreed to circulate the draft version of this chart (see Attachment B).

3. It was noted that the reports of the ACTE Advisory Board meetings would be publicly available on the ACTE and IATA websites.  (The web page address to the IATA site from where relevant documents can be downloaded is shown immediately below).
http://www.iata.org/idfs/committees/ccis/main_public.asp

Agenda Item 3: Update on Contacts with the Four Consultants

4. The two small/medium companies had accepted to go forward and prepare an offer.  However, the two large ones had declined.  It was agreed that Bernard Harrop would approach a large company and Dennis Bailey/Mike Muller would contact another large company with a view to offer them a chance to pitch for this business.

Agenda Item 4: Draft Procedures on How to Handle Consultant Selection Process

5.  It was agreed to invite all consultants to the next Advisory Board meeting in New York on 25 July.  The morning session would allow each consultant individual time to outline their proposal for the study into CCIS.  The afternoon session would open to all parties.  It would start with a data flow presentation followed by a general Q&A session.  The end of the meeting would be reserved for board members only to decide a way forward.

6. The group agreed to develop a "check list" to allow more scientific assessment of each consultant.  A draft list is shown in Attachment C.

Agenda Item 5: Progress Report Information Flow

7. It was agreed to defer this item to the next meeting.

Date and Place of Next Meeting/Conference Call

8. It was agreed that the next meeting would take place in New York on 25 July.

Attendance Record

COMPANY NAME TITLE TELEPHONE & FAX E-MAIL
ACTE Nancy
HOLTZMAN
(Chairperson)
Executive Director +1 703 683 1649
+1 703 683 2720
[email protected]
AMS Cheryl
HUTCHINSON
Senior PrincipalAMS
Corporate Travel
+1 703 267-2274
+1 703 227-4141
[email protected]
Astra Zeneca Pharmaceuticals Clive
ARMITAGE
Senior Manager, Travel,
Meetings & Fleet Purchasing
 
[email protected]
GlaxoSmithKline Dan
BAILLIE
Corporate Travel Manager   [email protected]
British Airways Justine
O’BRIEN
    [email protected]
GEBTA Bernard
HARROP
Director for Corporate
Services, Industry Affairs,
American Express Europe
+44 20 7943 3048
+44 1204 849 319
[email protected]
IATA Mike
MULLER
(Secretary)
Assistant Director,
Passenger Services
+41 22 799 2731
+41 22 799 2662
[email protected]
ITM Dennis
BAILY
Director +44 1268 292583
+44 1268 292966
[email protected]
NBTA Cindy
PERPER
    [email protected]
Oracle Marilyn
CLIFTON
Corporate Travel Manager
EMEA
+44 777-5845428
+44 1189-248529
[email protected]

Data Flow PDF

(a)  Established presence:                                                                         Scale   1 to 5
            USA

            Europe

(b)  Data Flow Expertise/Technology Understanding:
            Demonstrated experience in technology consulting

            Demonstrated understanding of data flow

            

(c)  Understanding of Airline:
            Historical pattern of behaviour

            Business model

(d)  Non biased:
            Ability to grasp issues surrounding study

            Ability to address issues in study without bias

             

(e)  available resources/capacity to perform:
            Time to do the study

            Staff to dedicate to study

            Priority of project

(f)  Credibility:
 
           Company code of ethics, mission statement

            References

            Ability to deliver projects on time

(g)  Thought Leadership:
           What have we missed?

Home | About | Membership | ACTE Sponsors | Resources | Events | Members Only | Contact Us | Canada | EMEA | Asia/Pacific | Site Map